Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2010-5-5
pubmed:abstractText
Inhibition of deacetylases represents a new treatment option for human cancer diseases. We applied the novel and potent pan-deacetylase inhibitor panobinostat (LBH589) to human hepatocellular carcinoma models and investigated by which pathways tumor cell survival is influenced. HepG2 (p53wt) and Hep3B (p53null) responded to panobinostat treatment with a reduction of cell proliferation and a significant increase in apoptotic cell death at low micromolar concentrations. Apoptosis was neither mediated by the extrinsic nor the intrinsic pathway but quantitative RT-PCR showed an upregulation of CHOP, a marker of the unfolded protein response and endoplasmic reticulum stress with subsequent activation of caspase 12. Dependent on the p53 status, a transcriptional upregulation of p21(cip1/waf1), an increased phosphorylation of H2AX, and an activation of the MAPK pathway were observed. In a subcutaneous xenograft model, daily i.p. injections of 10 mg/kg panobinostat lead to a significant growth delay with prolonged overall survival, mediated by reduced tumor cell proliferation, increased apoptosis and reduced angiogenesis in tumor xenografts. Panobinostat increased the acetylation of histones H3 and H4. Panobinostat is a well tolerated new treatment option for HCC that activates alternative pathways of apoptosis, also in p53-deficient tumors.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1875-8606
pubmed:author
pubmed:issnType
Electronic
pubmed:day
1
pubmed:volume
32
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
285-300
pubmed:meshHeading
pubmed-meshheading:20208142-Animals, pubmed-meshheading:20208142-Apoptosis, pubmed-meshheading:20208142-Carcinoma, Hepatocellular, pubmed-meshheading:20208142-Cell Proliferation, pubmed-meshheading:20208142-Cyclin-Dependent Kinase Inhibitor p21, pubmed-meshheading:20208142-Fibroblasts, pubmed-meshheading:20208142-Hep G2 Cells, pubmed-meshheading:20208142-Histone Deacetylase Inhibitors, pubmed-meshheading:20208142-Histones, pubmed-meshheading:20208142-Humans, pubmed-meshheading:20208142-Hydroxamic Acids, pubmed-meshheading:20208142-MAP Kinase Signaling System, pubmed-meshheading:20208142-Male, pubmed-meshheading:20208142-Mice, pubmed-meshheading:20208142-Mice, Inbred Strains, pubmed-meshheading:20208142-Neoplasm Transplantation, pubmed-meshheading:20208142-Transcription Factor CHOP, pubmed-meshheading:20208142-Tumor Burden, pubmed-meshheading:20208142-Tumor Suppressor Protein p53, pubmed-meshheading:20208142-Unfolded Protein Response
pubmed:year
2010
pubmed:articleTitle
The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis.
pubmed:affiliation
Department of Medicine 1, University Hospital Erlangen, Erlangen, Germany.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't